Merck reported strong Q2 performance with significant growth in key areas like Oncology and Vaccines, and raised full-year guidance despite some challenges in the China market. Management's optimistic tone and strategic investments underscore confidence in continued short-term growth. The positive momentum is likely to bolster investor sentiment in the near term.

[1]